Compare Johnson & Johnson (JNJ) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Starbucks Corp — how do they compare? Johnson & Johnson trades at $253.1 (market cap $609.12B), while Starbucks Corp trades at $105.63 (market cap $120.23B). The key difference: Johnson & Johnson is far larger — about 5.1× Starbucks Corp's market cap, and Starbucks Corp pays the higher dividend (2.35%). Which is the better fit depends on your goals.
| JNJ | SBUX | |
|---|---|---|
Market Cap | $609.12B | $120.23B |
Volume | 6,156,228 | 7,493,833 |
Sector | Health | Consumer Cyclical |
52-Week High | $267.24 | $108.37 |
52-Week Low | $163.70 | $78.46 |
Enterprise Value | $642.06B | $142.92B |
Dividend Yield | 2.12% | 2.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $253.04, up 1.23% today, with a bullish technical signal from moving averages and strong earnings beats in Q1 and Q2 2026. The company raised 2026 guidance, with revenue projected to exceed $100 billion, supported by robust profitability margins and a solid dividend track record. Recent news highlights institutional buying and analyst optimism following Q2 results.
Outlook remains positive with a consensus price target of $279.33, offering ~10% upside. Key risks include MedTech segment volatility and rising debt levels, but JNJ's diversified healthcare portfolio and AAA balance sheet provide stability for long-term investors amid market fluctuations.
Starbucks (SBUX) trades at $105.49, down 2.66% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue of $9.53 billion and 22% EPS growth, beating estimates, and raised FY2026 guidance. Recent news highlights AI-driven cost-cutting initiatives targeting $400 million in software savings. Valuation metrics show a high P/E of 80.53 and P/S of 3.13, while net income margin compressed to 3.89% in 2025.
The outlook is cautiously optimistic with analyst consensus leaning buy, targeting $108.86. Key opportunities include margin expansion from cost efficiencies and loyalty growth, but risks involve high valuation, competitive pressures, and execution on turnaround plans. Earnings momentum from recent beats supports near-term upside if operational improvements sustain.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
